Companies: 10,795·Total market cap: $144.5T
Xylo Technologies Ltd.

Xylo Technologies Ltd.

MDGSNASDAQHealthcare
$2.36
+$0.22(+10.28%)
Market Cap$178860624
P/E Ratio
52W High$7.17
52W Low$1.5396

Xylo Technologies Ltd. (MDGS) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

mdgs · pe ratio · data through Dec 31, 2023

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Xylo Technologies Ltd. (MDGS) measures how much investors pay for each dollar of the company's trailing earnings. MDGS's current PE ratio of N/A is calculated by dividing its stock price of $2.36 by its TTM earnings per share of -$8.36.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31

Forward P/E
1.43x
FY2023 est. EPS $1.65
Based on 1 analyst
EPS (TTM)
-$8.36
TTM · diluted EPS
PEG Ratio
-0.01
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Xylo Technologies Ltd. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2012 – 2023 · Annual
PE Ratio (TTM)
5Y Avg 2.9x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Medical - Devices · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Xylo Technologies Ltd.
Xylo Technologies Ltd.You
MDGS
$179MN/A-$8.36
Aptose Biosciences Inc.
Aptose Biosciences Inc.
APTO
$4MN/A$0.00
Gamida Cell Ltd.
Gamida Cell Ltd.
GMDA
$4MN/A-$0.42
Hillstream BioPharma, Inc.
Hillstream BioPharma, Inc.
HILS
$4MN/A-$1.12
Mallinckrodt plc
Mallinckrodt plc
MNK
$5MN/A-$17.48
Nabriva Therapeutics plc
Nabriva Therapeutics plc
NBRVF
$0MN/A-$21.32
Holdco Nuvo Group D.G Ltd. Ordinary Shares
Holdco Nuvo Group D.G Ltd. Ordinary Shares
NUVO
$6MN/A-$1.64

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 12 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2023-12-31Latest
FY2023
$-380.16
2022-12-31
FY2022
$-251.17
2021-12-31
FY2021
2.85x$5.27
2020-12-31
FY2020
$-30.80
2019-12-31
FY2019
$-108.89
2018-12-31
FY2018
$-1920.00
2017-12-31
FY2017
$-2795.32
2016-12-31
FY2016
$-31440.79
2015-12-31
FY2015
$-34243.89
2014-12-31
FY2014
$0.00

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Xylo Technologies Ltd. (MDGS) measures how much investors pay for each dollar of the company's trailing earnings. MDGS's current PE ratio of N/A is calculated by dividing its stock price of $2.36 by its TTM earnings per share of -$8.36.

PE Ratio = Stock Price ÷ EPS (TTM)
= $2.36 ÷ -$8.36 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

MDGS pe ratio · 6 questions

MDGS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.36 and TTM EPS of -$8.36. Data sourced from Financial Modeling Prep via MDGS's SEC 10-K and 10-Q filings.

MDGS PE ratioWhat is MDGS PE ratioCurrent PE ratio of MDGSMDGS PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Xylo Technologies Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09